198 related articles for article (PubMed ID: 32109251)
1. CpG ODN D35 improves the response to abbreviated low-dose pentavalent antimonial treatment in non-human primate model of cutaneous leishmaniasis.
Thacker SG; McWilliams IL; Bonnet B; Halie L; Beaucage S; Rachuri S; Dey R; Duncan R; Modabber F; Robinson S; Bilbe G; Arana B; Verthelyi D
PLoS Negl Trop Dis; 2020 Feb; 14(2):e0008050. PubMed ID: 32109251
[TBL] [Abstract][Full Text] [Related]
2. Clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in Peru.
Llanos-Cuentas A; Tulliano G; Araujo-Castillo R; Miranda-Verastegui C; Santamaria-Castrellon G; Ramirez L; Lazo M; De Doncker S; Boelaert M; Robays J; Dujardin JC; Arevalo J; Chappuis F
Clin Infect Dis; 2008 Jan; 46(2):223-31. PubMed ID: 18171254
[TBL] [Abstract][Full Text] [Related]
3. Antimony susceptibility of Leishmania isolates collected over a 30-year period in Algeria.
Eddaikra N; Ait-Oudhia K; Kherrachi I; Oury B; Moulti-Mati F; Benikhlef R; Harrat Z; Sereno D
PLoS Negl Trop Dis; 2018 Mar; 12(3):e0006310. PubMed ID: 29561842
[TBL] [Abstract][Full Text] [Related]
4. CpG oligodeoxynucleotides protect normal and SIV-infected macaques from Leishmania infection.
Verthelyi D; Gursel M; Kenney RT; Lifson JD; Liu S; Mican J; Klinman DM
J Immunol; 2003 May; 170(9):4717-23. PubMed ID: 12707351
[TBL] [Abstract][Full Text] [Related]
5. Prevention and treatment of cutaneous leishmaniasis in primates by using synthetic type D/A oligodeoxynucleotides expressing CpG motifs.
Flynn B; Wang V; Sacks DL; Seder RA; Verthelyi D
Infect Immun; 2005 Aug; 73(8):4948-54. PubMed ID: 16041009
[TBL] [Abstract][Full Text] [Related]
6. Type I Interferon Signaling Is Required for CpG-Oligodesoxynucleotide-Induced Control of
Schleicher U; Liese J; Justies N; Mischke T; Haeberlein S; Sebald H; Kalinke U; Weiss S; Bogdan C
Front Immunol; 2018; 9():79. PubMed ID: 29459858
[TBL] [Abstract][Full Text] [Related]
7. Antimonial susceptibility and in vivo behaviour of Leishmania major isolates collected in Algeria before and after treatment.
Naouel E; Ihcene KD; Sofiane B; Khatima AO; Razika B; Bruno O; Zoubir H; Denis S
Acta Trop; 2018 Apr; 180():7-11. PubMed ID: 29278674
[TBL] [Abstract][Full Text] [Related]
8. Species-specific antimonial sensitivity in Leishmania is driven by post-transcriptional regulation of AQP1.
Mandal G; Mandal S; Sharma M; Charret KS; Papadopoulou B; Bhattacharjee H; Mukhopadhyay R
PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003500. PubMed ID: 25714343
[TBL] [Abstract][Full Text] [Related]
9. Topical tamoxifen in the therapy of cutaneous leishmaniasis.
Trinconi CT; Reimão JQ; Bonano VI; Espada CR; Miguel DC; Yokoyama-Yasunaka JKU; Uliana SRB
Parasitology; 2018 Apr; 145(4):490-496. PubMed ID: 28274283
[TBL] [Abstract][Full Text] [Related]
10. American tegumentary leishmaniasis: Is antimonial treatment outcome related to parasite drug susceptibility?
Yardley V; Ortuno N; Llanos-Cuentas A; Chappuis F; Doncker SD; Ramirez L; Croft S; Arevalo J; Adaui V; Bermudez H; Decuypere S; Dujardin JC
J Infect Dis; 2006 Oct; 194(8):1168-75. PubMed ID: 16991093
[TBL] [Abstract][Full Text] [Related]
11. Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis.
Arevalo J; Ramirez L; Adaui V; Zimic M; Tulliano G; Miranda-Verástegui C; Lazo M; Loayza-Muro R; De Doncker S; Maurer A; Chappuis F; Dujardin JC; Llanos-Cuentas A
J Infect Dis; 2007 Jun; 195(12):1846-51. PubMed ID: 17492601
[TBL] [Abstract][Full Text] [Related]
12. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies.
Herwaldt BL; Berman JD
Am J Trop Med Hyg; 1992 Mar; 46(3):296-306. PubMed ID: 1313656
[TBL] [Abstract][Full Text] [Related]
13. Use of thermolytic protective groups to prevent G-tetrad formation in CpG ODN type D: structural studies and immunomodulatory activity in primates.
Puig M; Grajkowski A; Boczkowska M; Ausín C; Beaucage SL; Verthelyi D
Nucleic Acids Res; 2006; 34(22):6488-95. PubMed ID: 17130156
[TBL] [Abstract][Full Text] [Related]
14. Alterations in phenotypic profiles of peripheral blood cells from patients with human American cutaneous leishmaniasis following treatment with an antimonial drug and a vaccine.
Botelho AC; Mayrink W; Oliveira RC
Acta Trop; 2009 Nov; 112(2):143-8. PubMed ID: 19631187
[TBL] [Abstract][Full Text] [Related]
15. Susceptibility of clinically sensitive and resistant Leishmania to pentavalent antimony in vitro.
Berman JD; Chulay JD; Hendricks LD; Oster CN
Am J Trop Med Hyg; 1982 May; 31(3 Pt 1):459-65. PubMed ID: 7081539
[TBL] [Abstract][Full Text] [Related]
16. Resistance to antimony and treatment failure in human Leishmania (Viannia) infection.
Rojas R; Valderrama L; Valderrama M; Varona MX; Ouellette M; Saravia NG
J Infect Dis; 2006 May; 193(10):1375-83. PubMed ID: 16619185
[TBL] [Abstract][Full Text] [Related]
17. The effects of induced diabetes and cutaneous Leishmania infection on the pharmacokinetics of antimony in hamsters.
Radwan MA; Al Jaser MH; Al Rayes ZR
Ann Trop Med Parasitol; 2007 Mar; 101(2):133-42. PubMed ID: 17316499
[TBL] [Abstract][Full Text] [Related]
18. Development of Nonaggregating Poly-A Tailed Immunostimulatory A/D Type CpG Oligodeoxynucleotides Applicable for Clinical Use.
Aoshi T; Haseda Y; Kobiyama K; Narita H; Sato H; Nankai H; Mochizuki S; Sakurai K; Katakai Y; Yasutomi Y; Kuroda E; Coban C; Ishii KJ
J Immunol Res; 2015; 2015():316364. PubMed ID: 26380317
[TBL] [Abstract][Full Text] [Related]
19. Treatment of New World cutaneous and mucosal leishmaniases.
Berman JD
Clin Dermatol; 1996; 14(5):519-22. PubMed ID: 8889330
[TBL] [Abstract][Full Text] [Related]
20. The Immunology of a Healing Response in Cutaneous Leishmaniasis Treated with Localized Heat or Systemic Antimonial Therapy.
Lakhal-Naouar I; Slike BM; Aronson NE; Marovich MA
PLoS Negl Trop Dis; 2015; 9(10):e0004178. PubMed ID: 26485398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
